New sickle cell drug candidate enters first human tests

NCT ID NCT04255875

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called PF-07209326 in 52 people, first in healthy volunteers and then in patients with sickle cell disease. The main goal was to check safety and how the body processes the drug. Researchers also looked for any early signs that the drug might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-07209326
What this could lead to: If this drug proves safe and shows early signs of working, it could point toward a new treatment option for sickle cell disease.
What could go wrong: This is a very early Phase 1 trial with only 52 participants, focused mainly on safety. It is too small and early to know if the drug will actually help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SICKLE CELL ANEMIA

Contacts and locations

Locations

CUIMC Research Pharmacy

New York, New York, 10032, United States
CUMC Research Pharmacy

New York, New York, 10032, United States
Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center

Atlanta, Georgia, 30322, United States
Columbia University Medical Center - Herbert Irving Pavilion

New York, New York, 10032, United States
Foundation for Sickle Cell Disease Research

Hollywood, Florida, 33023, United States
Foundation for Sickle Cell Disease Research

Hollywood, Florida, 33024, United States
Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, 33908, United States
Howard University College of Medicine

Washington D.C., District of Columbia, 20060, United States
Lee Health - Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, 33908, United States
Memorial Hermann clinical research unit

Houston, Texas, 77030, United States
New Haven Clinical Research Unit

New Haven, Connecticut, 06511, United States
Prism Research LLC dba Nucleus Network

Saint Paul, Minnesota, 55114, United States
UT Physicians Comprehensive Sickle Cell Center Houston

Houston, Texas, 77004, United States
UT Physicians Comprehensive Sickle Cell Center Houston

Houston, Texas, 77030, United States
University of Illinois at Chicago

Chicago, Illinois, 60612, United States
University of Illinois at Chicago Clinical Research Center

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.